CA027-002: BMS-986253 and Nivolumab in Advanced Cancers
Research type
Research Study
Full title
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
IRAS ID
250129
Contact name
Gary Middleton
Contact email
Sponsor organisation
Bristol-Myers Squibb International Corporation
Eudract number
2018-000340-26
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
4 years, 2 months, 25 days
Research summary
Patients that have advanced solid tumours which progress after standard treatment is given, generally have a poor prognosis and very limited options for a cure. For this very reason there is a significant need to develop alternative therapy approaches for the treatment of these advanced cancers.
Immunotherapy is a therapy based on the stimulation of the body's own immune system to attack cancer cells. The investigational drugs BMS-986253 and nivolumab are immunotherapy agents, which help the immune system to recognise and kill cancer cells.
The combination of two immunotherapy agents could lead to a better effect to kill cancer cells by attacking the cells with the bodies immune system through different pathways.
REC name
South Central - Oxford C Research Ethics Committee
REC reference
19/SC/0027
Date of REC Opinion
28 Feb 2019
REC opinion
Further Information Favourable Opinion